Cargando...
Debugging the Black Box
A better understanding of the mechanisms by which tumor rejection succeeds and fails is needed to improve immunotherapies. Here, Anagnostou and colleagues find that mutations predicted to be the most immunogenic are preferentially lost when cancer progresses through checkpoint blockade.
Gardado en:
| Publicado en: | Cancer Discov |
|---|---|
| Autor Principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2017
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5341699/ https://ncbi.nlm.nih.gov/pubmed/28264866 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-17-0070 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|